Key Highlights

  • Phase 2/3 Study 302 met all primary and key secondary endpoints.
  • Data showed significant increases in non-vellus hair count with onset by month two.
  • Safety profile was described as placebo-like.
  • Shares closed up 5.19% at $111.32; twelve-month data due in second half of 2026.

Veradermics Incorporated (NASDAQ: MANE) shares closed up 5.19% at $111.32 after the company shared Phase 2/3 data for its male pattern hair loss candidate VDPHL01 at the AAD Innovation Academy on July 17, 2026.

What Happened

The Phase 2/3 study, known as Study 302, met all primary and key secondary endpoints, according to data noted April 27, 2026.

The study reported highly significant increases in non-vellus hair count, strong patient-reported improvement rates, rapid onset of effect by month two, and a placebo-like safety profile.

Market Reaction

Veradermics, valued at approximately $4.65 billion, saw shares rise 5.19% to close at $111.32 following the data presentation.

Outlook

Twelve-month data from Study 302 is anticipated in the second half of 2026.

What is VDPHL01?

VDPHL01 is Veradermics' Phase 2/3 candidate for male pattern hair loss, studied in the trial known as Study 302.

What did the Phase 2/3 data show?

The study met all primary and key secondary endpoints, with significant increases in non-vellus hair count and a placebo-like safety profile.

When is the next data readout for VDPHL01?

Twelve-month data from Study 302 is anticipated in the second half of 2026.